Frank Breuckmann

Frank Breuckmann

Auto-generated profile, based on publicly available information

Frank Breuckmann

Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen, University Duisburg-Essen, Essen, Germany

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2008 in European Heart Journal
Verified
Journal Article
Open access
PDF file
SMStefan Möhlenkamp
Stefan Möhlenkamp
NLNils Lehmann
Nils Lehmann
FBFrank Breuckmann
Frank Breuckmann
MBMartina Bröcker-Preuss
Martina Bröcker-Preuss
KNKai Nassenstein
Kai Nassenstein
OIon behalf of the Marathon Study Investigators and the Heinz Nixdorf Recall Study Investigators
on behalf of the Marathon Study Investigators and the Heinz Nixdorf Recall Study Investigators
To quantify the prevalence of coronary artery calcification (CAC) in relation to cardiovascular risk factors in marathon runners, and to study its role for myocardial damage and coronary events. In 108 apparently healthy male marathon runners aged ≥50 years, with ≥5 marathon competitions during the previous three years, the running history, Framingham risk score (FRS), CAC, and presence of myocardial late gadolinium enhancement (LGE) were measured. Control groups were matched by age (8:1) and FRS (2:1) from the Heinz Nixdorf Recall Study. The FRS in marathon runners was lower than in age-matched controls (7 vs. 11%, P < 0.0001). However, the CAC distribution was similar in marathon runners and age-matched controls (median CAC: 36 vs. 38, P = 0.36) and higher in marathon runners than in FRS-matched controls (median CAC: 36 vs. 12, P = 0.02). CAC percentile values and number of marathons independently predicted the presence of LGE (prevalence = 12%) (P = 0.02 for both). During follow-up after 21.3 ± 2.8 months, four runners with CAC ≥ 100 experienced coronary events. Event-free survival was inversely related to CAC burden (P = 0.018). Conventional cardiovascular risk stratification underestimates the CAC burden in presumably healthy marathon runners. As CAC burden and frequent marathon running seem to correlate with subclinical myocardial damage, an increased awareness of a potentially higher than anticipated coronary risk is warranted.

1 April 2009 in Radiology
Verified
Journal Article
Closed access
FBFrank Breuckmann
Frank Breuckmann
SMStefan Möhlenkamp
Stefan Möhlenkamp
KNKai Nassenstein
Kai Nassenstein
NLNils Lehmann
Nils Lehmann
SLSusanne Ladd
Susanne Ladd
JBJörg Barkhausen
Jörg Barkhausen
To prospectively analyze the myocardial distribution of late gadolinium enhancement (LGE) with delayed-enhancement cardiac magnetic resonance (MR) imaging, to compare the prevalence of this distribution in nonprofessional male marathon runners with that in asymptomatic control subjects, and to examine the prognostic role of LGE. Institutional review board and ethics committee approval were obtained for this study, and all subjects provided written informed consent. Two-dimensional inversion-recovery segmented k-space gradient-echo MR sequences were performed after administration of a gadolinium-containing contrast agent in 102 ostensibly healthy male runners aged 50-72 years who had completed at least five marathons during the past 3 years and in 102 age-matched control subjects. Predominantly subendocardial regions of LGE typical of myocardial infarction (hereafter, coronary artery disease [CAD] pattern) were distinguished from a predominantly midmyocardial patchy pattern of LGE (hereafter, non-CAD pattern). Marathon runners with LGE underwent repeat cardiac MR imaging and additional adenosine perfusion imaging. Runners were followed up for a mean of 21 months +/- 3 (standard deviation) after initial presentation. The chi(2), Fisher exact, and McNemar exact tests were used for comparisons. Event-free survival rates were estimated with the Kaplan-Meier method, and overall group differences were evaluated with log-rank statistics. Of the 102 runners, five had a CAD pattern of LGE, and seven had a non-CAD pattern of LGE. The CAD pattern of LGE was located in the territory of the left anterior descending coronary artery more frequently than was the non-CAD pattern (P = .0027, Fisher exact test). The prevalence of LGE in runners was higher than that in age-matched control subjects (12% vs 4%; P = .077, McNemar exact test). The event-free survival rate was lower in runners with myocardial LGE than in those without myocardial LGE (P < .0001, log-rank test). Ostensibly healthy marathon runners have an unexpectedly high rate of myocardial LGE, and this may have diagnostic and prognostic relevance.

1 July 2005 in Archives of Dermatology
Verified
Journal Article
Open access
PDF file
Alexander KreuterAlexander Kreuter
Alexander Kreuter
TGThilo Gambichler
Thilo Gambichler
FBFrank Breuckmann
Frank Breuckmann
SRSebastian Rotterdam
Sebastian Rotterdam
MFMarcus Freitag
Marcus Freitag
PAPeter Altmeyer
Peter Altmeyer
Localized scleroderma (LS) or morphea denotes a spectrum of disorders characterized by hardening and thickening of different levels of the dermis, subcutis, and sometimes underlying soft tissue and bone. Localized scleroderma has been classified into plaque, generalized, bullous, linear including scleroderma en coup de sabre, and deep forms such as morphea profunda.1 Hence, the clinical spectrum of LS ranges from discrete, circumscribed sclerotic plaques of cosmetic importance only to more severe variants that may have devastating effects, such as growth retardation, muscle atrophy, flexion contractures, and psychological disability. The etiology of LS remains unknown, but autoimmune, genetic, infectious, and environmental factors have been implicated.

1 April 2005 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
TGThilo Gambichler
Thilo Gambichler
FBFrank Breuckmann
Frank Breuckmann
SBStefanie Boms
Stefanie Boms
PAPeter Altmeyer
Peter Altmeyer
AKAlexander Kreuter
Alexander Kreuter

1 September 2004 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
AKAlexander Kreuter
Alexander Kreuter
TGThilo Gambichler
Thilo Gambichler
FBFrank Breuckmann
Frank Breuckmann
FPFrank M. Pawlak
Frank M. Pawlak
MSMarkus Stücker
Markus Stücker
MFMarcus Freitag
Marcus Freitag

20 September 2004 in BMC Dermatology
Verified
Journal Article
Open access
PDF file
FBFrank Breuckmann
Frank Breuckmann
TGThilo Gambichler
Thilo Gambichler
PAPeter Altmeyer
Peter Altmeyer
Alexander KreuterAlexander Kreuter
Alexander Kreuter
Background: Broad-band UVA, long-wave UVA1 and PUVA treatment have been described as an alternative/adjunct therapeutic option in a number of inflammatory and malignant skin diseases. Nevertheless, controlled studies investigating the efficacy of UVA irradiation in connective tissue diseases and related disorders are rare. Methods: Searching the PubMed database the current article systematically reviews established and innovative therapeutic approaches of broad-band UVA irradiation, UVA1 phototherapy and PUVA photochemotherapy in a variety of different connective tissue disorders. Results: Potential pathways include immunomodulation of inflammation, induction of collagenases and initiation of apoptosis. Even though holding the risk of carcinogenesis, photoaging or UV-induced exacerbation, UVA phototherapy seems to exhibit a tolerable risk/benefit ratio at least in systemic sclerosis, localized scleroderma, extragenital lichen sclerosus et atrophicus, sclerodermoid graft-versus-host disease, lupus erythematosus and a number of sclerotic rarities. Conclusions: Based on the data retrieved from the literature, therapeutic UVA exposure seems to be effective in connective tissue diseases and related disorders. However, more controlled investigations are needed in order to establish a clear-cut catalogue of indications.